Vutiglabridin for Parkinson's Disease
Trial Overview
flowchart TD
clinical_trials_vutiglabridin_["Vutiglabridin for Parkinsons Disease"]
style clinical_trials_vutiglabridin_ fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_vuti_0["Trial Overview"]
clinical_trials_vutiglabridin_ -->|"includes"| clinical_trials_vuti_0
style clinical_trials_vuti_0 fill:#81c784,stroke:#333,color:#000
clinical_trials_vuti_1["Study Design"]
clinical_trials_vutiglabridin_ -->|"includes"| clinical_trials_vuti_1
style clinical_trials_vuti_1 fill:#ef5350,stroke:#333,color:#000
clinical_trials_vuti_2["Study Objectives"]
clinical_trials_vutiglabridin_ -->|"includes"| clinical_trials_vuti_2
style clinical_trials_vuti_2 fill:#ffd54f,stroke:#333,color:#000
clinical_trials_vuti_3["Background and Rationale"]
clinical_trials_vutiglabridin_ -->|"includes"| clinical_trials_vuti_3
style clinical_trials_vuti_3 fill:#ce93d8,stroke:#333,color:#000
clinical_trials_vuti_4["Parkinsons Disease Burden"]
clinical_trials_vutiglabridin_ -->|"includes"| clinical_trials_vuti_4
style clinical_trials_vuti_4 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_vuti_5["Unmet Therapeutic Needs"]
clinical_trials_vutiglabridin_ -->|"includes"| clinical_trials_vuti_5
style clinical_trials_vuti_5 fill:#81c784,stroke:#333,color:#000
Clinical Trial Identifier: NCT06329141
Status: Recruiting
Sponsor: Glaceum Inc.
Phase: Phase IIa
Intervention: Vutiglabridin vs placebo
Study Design
...Vutiglabridin for Parkinson's Disease
Trial Overview
Mermaid diagram (expand to render)
Clinical Trial Identifier: NCT06329141
Status: Recruiting
Sponsor: Glaceum Inc.
Phase: Phase IIa
Intervention: Vutiglabridin vs placebo
Study Design
- Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups, Phase 2a Clinical Trial to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients
- Intervention: Vutiglabridin (oral) vs placebo
- Randomization: Parallel groups design
- Blinding: Double-blind
- Study Population: Early Parkinson's disease patients (Hoehn & Yahr stages 1-2)
- Duration: Multi-dose, multi-center trial
- Sites: Multiple centers in South Korea
Study Objectives
Primary Endpoints:
- Efficacy: Change in Unified Parkinson's Disease Rating Scale (UPDRS) scores
- Safety: Adverse events, laboratory assessments, vital signs
Secondary Endpoints:
- Quality of life measures
- Motor function assessments
- Pharmacokinetic evaluations
Background and Rationale
Parkinson's Disease Burden
Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease, affecting approximately 10 million people worldwide. The disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to motor symptoms including bradykinesia, resting tremor, rigidity, and postural instability[@kalia2023].
Despite significant advances in symptomatic treatment, Parkinson's disease remains inexorably progressive, with no approved therapies that demonstrably slow or halt neurodegeneration. The unmet need for disease-modifying therapies remains substantial.
Unmet Therapeutic Needs
Current PD treatments address symptoms but not underlying neurodegeneration:
| Category | Examples | Limitation |
|----------|----------|------------|
| Dopamine precursors | Levodopa/carbidopa | Long-term complications (dyskinesia) |
| Dopamine agonists | Pramipexole, ropinirole | Side effects (impulse control) |
| MAO-B inhibitors | Rasagiline, safinamide | Modest symptomatic benefit |
| COMT inhibitors | Entacapone | Limited efficacy alone |
The development of disease-modifying therapies remains the paramount goal in PD research[@schapira2019].
Mechanism of Action
Compound Overview
Vutiglabridin is a small molecule therapeutic agent developed by Glaceum Inc. While the specific molecular mechanism has not been publicly disclosed, the sponsor's development program suggests targeting of pathways relevant to Parkinson's disease neurodegeneration.
Potential Mechanisms
Based on the therapeutic area and development approach, Vutiglabridin may act through one or more of the following mechanisms:
1. Neuroprotection
Multiple neuroprotective pathways are under investigation in PD:
- Mitochondrial function preservation
- Oxidative stress reduction
- Apoptosis inhibition
- Neurotrophic support enhancement
2. Anti-inflammatory Effects
Neuroinflammation contributes to PD progression:
- Microglial activation modulation
- Cytokine production reduction
- Blood-brain barrier protection
3. Protein Homeostasis
Impaired protein clearance is central to PD pathogenesis:
- Autophagy enhancement
- Proteasome function support
- Alpha-synuclein aggregation inhibition
4. Synaptic Function
Synaptic dysfunction occurs early in PD:
- Dopamine release modulation
- Synaptic plasticity preservation
- Neural network stabilization
Preclinical Development
Glaceum Inc. has conducted Phase 1 trials establishing:
- Safety and tolerability in healthy subjects
- Pharmacokinetic properties
- Maximum tolerated dose
- Preliminary efficacy signals
Clinical Development Strategy
Phase 1 Results
Phase 1 studies typically establish:
- Safety profile across dose ranges
- Pharmacokinetic/pharmacodynamic relationships
- Preliminary target engagement
- Selection of doses for Phase 2
Phase 2a Design Rationale
The Phase 2a trial design reflects:
- Early disease population (greater neuroprotective potential)
- Placebo control for efficacy signal detection
- Double-blind to minimize bias
- Multi-center for enrollment efficiency
Patient Selection
Early PD patients (Hoehn & Yahr 1-2) are ideal for disease-modifying therapy because:
- Substantial dopaminergic neuron reserve remains
- Less advanced pathology may respond better
- Fewer confounding comorbidities
- Better able to complete trial assessments
Therapeutic Implications
Disease Modification Potential
If Vutiglabridin demonstrates efficacy, implications include:
First-in-class mechanism: Novel therapeutic approach for PD
Neuroprotection: Preservation of remaining neurons
Symptomatic benefit: Potential for combined effects
Early intervention: Best used before extensive degenerationCompetitive Landscape
| Agent | Company | Mechanism | Stage |
|-------|---------|-----------|-------|
| Vutiglabridin | Glaceum | Unknown | Phase 2a |
| BIIB122 | Biogen | LRRK2 inhibitor | Phase 2b |
| Cinquanod | Novartis | α-syn antibody | Phase 2 |
| Prasinezumab | Roche | α-syn antibody | Phase 3 |
| Dipraglurant | Addex | mGluR5 antagonist | Phase 3 |
Advantages of Small Molecules
Compared to biologics, small molecule therapeutics offer:
- Oral administration convenience
- Better brain penetration
- Lower manufacturing costs
- No immunogenicity concerns
Clinical Trial Analysis
Endpoints Assessment
UPDRS (Unified Parkinson's Disease Rating Scale)
- Part I: Non-motor experiences of daily living
- Part II: Motor experiences of daily living
- Part III: Motor examination (primary)
- Part IV: Motor complications
Changes in UPDRS Part III (motor examination) are the standard primary endpoint for PD clinical trials.
Safety Monitoring
Comprehensive safety assessment includes:
- Adverse event reporting
- Physical examination
- Vital signs
- Laboratory values (hematology, chemistry)
- Electrocardiogram
- Neurological examination
Biomarker Development
Potential biomarkers for PD trials:
- Neurodegeneration markers: Neurofilament light chain (NfL), phosphorylated neurofilament heavy chain (pNfH)
- α-synuclein species: Oligomers, seeding activity (RT-QuIC)
- Imaging biomarkers: DaTscan, MRI volumetric measures
- Clinical biomarkers: Smell test, REM sleep behavior disorder
Research Context
PD Clinical Trial Landscape
The PD clinical trial landscape has evolved significantly:
Disease modification focus: Shift from symptomatic to neuroprotective
Biomarker integration: Including biomarker endpoints
Personalized approaches: Genetic stratification, phenotype-based selection
Combination strategies: Multi-target therapiesChallenges in PD Clinical Trials
PD trials face significant challenges:
- Placebo responses: Historically substantial (15-30% improvement)
- Disease heterogeneity: Variable progression rates
- Long trials: Disease modification requires extended observation
- Endpoint sensitivity: Need sensitive measures of progression
Lessons from Successful Programs
Recent successes provide guidance:
- Rasagiline: Validated delayed-start design for disease modification
- Inosine: Demonstrated urate elevation is safe (not efficacy)
- Amantadine: Extended-release formulation (ADS-5102) approved for dyskinesia
Future Development
Pivotal Trial Requirements
Successful Phase 2a would advance to Phase 3:
- Larger sample size (300-600 patients)
- Extended treatment duration (12-24 months)
- Global multi-center design
- Comprehensive biomarker program
- Regulatory interactions
Regulatory Pathways
Potential approval pathways:
- Standard approval (clinical endpoints)
- Accelerated approval (biomarker-based)
- Breakthrough therapy designation
Combination Potential
Future development may explore:
- Vutiglabridin + standard-of-care (levodopa)
- Vutiglabridin + other disease-modifying agents
- Vutiglabridin + physical therapy/exercise
Safety Considerations
Expected Safety Profile
Based on Phase 1 data and compound class:
- Generally favorable tolerability
- Low rates of serious adverse events
- Manageable side effect profile
Monitoring Requirements
Trial participants will be monitored for:
- Gastrointestinal effects
- CNS effects
- Cardiovascular effects
- Hepatic/renal function
Drug Interactions
Assessment of:
- CYP enzyme interactions
- Transport protein interactions
- PD medication interactions
Cross-Links
- [Parkinson's Disease](/diseases/parkinsons-disease) - Primary disease context
- [Early Parkinson's Disease](/diseases/early-parkinson-disease) - Target population
- [Parkinson's Disease Clinical Trials](/clinical-trials/parkinsons-disease) - Related trials
- [Dopamine Agonists](/therapeutics/dopamine-agonists) - Current treatments
- [Neuroprotection](/mechanisms/neuroprotection-pathways) - Related mechanism
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-parkinsons) - Key pathway
- [Neuroinflammation](/mechanisms/neuroinflammation) - Disease mechanism
Clinical Sites
The trial is being conducted at multiple sites in South Korea:
- [The Catholic University of Korea](/genes/cat)
- [Kyunghee University Medical Center](/genes/ung)
- Korea University Guro Hospital
- [Additional sites as needed](/genes/eed)
References
[NCT06329141 - Vutiglabridin in Early Parkinson's Disease](https://clinicaltrials.gov/study/NCT06329141)
[Schapira et al., Novel pharmacological targets for Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31145791/)
[Kalia & Lang, Parkinson's disease: concepts and controversies (2023)](https://pubmed.ncbi.nlm.nih.gov/37680378/)
[Obeso et al., Past, present, and future of Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32989290/)
[Jankovic & Tan, Disease progression in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37506123/)
[Lang AE, et al., Disease modification in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35040892/)
[Poewe W, et al., Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35263452/)